Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe they are waiting out this market correction, just a thought.
The markets have been in a blood bath lately.
Moving up fast :)
.012 one day we will be looking back at this low price and wish we had more dry powder to load the boat.
FLCR Boardmarks are UpChanging, Word is getting out, eom
Testimonials from the Kodiac site, FLCR
http://www.kodiak-capital.us/home/testimonials/
HERE'S WHAT SOME OF OUR AFFILIATES ARE SAYING
"Kodiak's emphatic devotion for betting on companies outside the small magical circle of apparent "sure winners" is getting around; we have been thrilled with our partnership and are more than impressed with their incubating service alongside their capital commitment. They know how to get-the-job-done!"
Jeremy Black, Advisory Board, LivetoClose.com
"Kodiak has provided us with a fair and flexible financing solution to assist us with the growth of our business. They were very patient in assisting us with properly structuring the investment and provided immediate response time with execution when we needed it the most. We are happy to have them as an investment partner."
Lee Rodne, CEO, Allied Healthcare Group Limited
"Kodiak truly cares about the people and companies they fund. They offer very desirable terms much better than other VC deals. They acted in one week while other sources would take months. They aren't interested in taking control positions and have a great overall reputation and investor following. I can truly say it's the most pleasant investor relationship I have ever had. Kodiak is the real deal!"
Corey Park, CEO, Dealite.me, Inc.
"We have been partners with Kodiak for nearly a year now and it has been the most positive experience I have had with an institutional investor. Kodiak recognizes the uphill battle often fought by young companies and is willing to share the risk from the onset. Negotiations are straight forward, deals are fair and Kodiak cooperates closely to generate value for all involved. We will always give Kodiak the opportunity to execute in any new transaction that we may consider."
Greg Lambrecht, CEO, Lifestyle Wireless, Inc.
"Kodiak is extremely well connected and are very strategic thinkers. As such, they have been an awesome asset in helping us connect with the right people and companies throughout key inflection points in the evolution of our business and the 'go-public' process. They are fanatically founder friendly and just truly good people. I'd highly recommend Kodiak to any entrepreneur without exception."
Warren Wang, CEO, ChineseInvestors.com, Inc.
"Kodiak's incredible networking and business development power is one of those things every entrepreneur needs. Their determination to help and see things through is an amazing asset to any startup and we are grateful to have them as an investor."
Delmar Janovicz, CEO, BizAuctions, Inc.
"Kodiak is one of the most amazing investors I've ever known and I feel extremely lucky to work with them. They have been there every step of the way as we built our company and has been in the trenches ensuring we built the most amazing product possible. Their expertise in the space helped us focus the product and they have done everything from help us nail down our branding and deck narrative as well as connected us to ideal partners and customers. The entire Kodiak team works their ass off for their portfolio - do everything you can to become a part of it!"
Michael Bagley, CEO, Jellyfish INTEL, inc.
"Smart investor that knows how to connect with entrepreneurs and loves backing people with disruptive personalities and the skills to build and grow world-changing products and services. I highly recommend partnering with Kodiak."
Christopher Kolb, President, Safe Technologies International, Inc.
"Kodiak is very professional, personable, and attentive to their business deals and with everyone they work with.They are extremely knowledgeable about the funding industry and quite savvy in designing funding strategies for their clients. Kodiak is also very accessible and responds quickly to their clients. I found their funding terms to be favorable and superior to most any other funding source. They are truly interested in creating a win-win for everyone in the process. I’d highly recommend Kodiak as an investor."
Michael Holt, President, Penny Auction Solutions, Inc.
"We’ve enjoyed partnering with Kodiak. The fact that Kodiak is a well established venture firm structuring private equity investments for almost a decade made our decision to partner with them much easier. Their multiple equity investments have delivered as promised and have been a simple and efficient source of capital for us. We look forward to continuing our partnership for years to come."
Edjir Liang, Director, China Kangtai Cactus Bio-tech, Inc.
"One of the most intellectually disciplined and gifted groups of people I know. Kodiak has a lion's heart and has acquired the rare skill of balancing financial interests with entrepreneurial purpose without selling their soul. A genuine mensch who has helped with unconditional and straight forward advice every time. They either do or do not and will let you know that - a true thought leader of our time, not only in finance - I recommend Kodiak as a friend, mentor, advisor, investor or board member any time."
Vincent Browne, CEO, Flint Telecom Group, Inc.
"During the last four years the professionals at Kodiak have supported our capital needs. They are incredily responsive and have provided flexibility, sound advice and highly creative financial solutions for our working capital, re-structuring and expansion needs. Based on integrity, mutual respect, and strict adherence to compliance issues, the Kodiak team excels and delivers, they are proven and have provided capital in highly irregular and disruptive markets."
John Ryder, CEO, Dianor Resources, Inc.
"Kodiak is, well, Kodiak. They kick ass and have a no bs, no frills, just get the job done attitude towards investing. They are calculated risks experts. I love being part of the Kodiak portfolio!"
Edgar Arvelo, CEO, My Complete Care, Inc.
Be aware that FLCR is a Fully Reporting OTCBB company, fully compliant with the SEC.
Pull up your boot straps and buckle them up.
If Kodiac puts out the word as we know it, They are a Wall Street capital firm, FLCR will be soaring well above the 5 days ago pps of .046.
FLCR has a relatively low float.
Date Open High Low Close Volume Adj
Close
2015/01/08 0.0090 0.015 0.0068 0.0075 946,500 0.0075
2015/01/07 0.012 0.012 0.010 0.010 295,000 0.010
2015/01/06 0.0175 0.020 0.0116 0.0116 215,000 0.0116
2015/01/05 0.032 0.032 0.018 0.018 123,000 0.018
2015/01/02 0.025 0.0465 0.025 0.0465 35,235 0.0465
2014/12/31 0.027 0.0455 0.025 0.0455 23,000 0.0455
2014/12/30 0.0455 0.0455 0.0455 0.0455 - 0.0455
2014/12/29 0.0425 0.0455 0.0425 0.0455 20,000 0.0455
2014/12/26 0.0465 0.0465 0.0465 0.0465 2,331 0.0465
2014/12/24 0.035 0.035 0.035 0.035 7,000 0.035
2014/12/23 0.035 0.046 0.035 0.046 13,000 0.046
2014/12/22 0.023 0.046 0.022 0.046 48,360 0.046
2014/12/19 0.033 0.033 0.018 0.023 266,200 0.023
2014/12/18 0.018 0.035 0.018 0.035 490,214 0.035
SRT8, call my bro's cell, he is with me now. eom
I wonder if they will have the balls to take it down to four digits? Time to wake up Grueto after the fish company makes a delivery. Wow. Someone has got to summon the nobo/obo lists and start monitoring.
You are right SRT8.
SRT8, well thought out post, however consider the vampires of wallstreet are again shorting in the trillions of dollars.
There will be margin calls when the dow/s&p/naz are losing 300 points a day.
Don't get disappointed just because we go into the tank, so many others are, too.
We got to wait for oil to bottom out as the vampires/demons are using OIL as an excuse to crash the market, that is how these creeps make their money. I wouldn't be surprised for the Marxists/muslims to take the dow down to 14k, or less, on this notion. Who knows, we will see.
I don't put this on Kodiac.
I'd give it a another couple of weeks, or few, of pain in the markets. All you got to do is watch the movie actors on cnbc cry in the blues while the market crashes, and then all of a sudden they are given a New script with happy faces as if nothing happened in our markets. And then they say, buy, buy, buy. They on the payroll.
This is the fourth major market adjustment in 15 years, and imho, it is not done yet.
Who know! But good luck and give the wife a hug!
Happy New Year harr449, hoping Dino gets this going for us 2015.
Thanks Dino and Harr, Happy New Year :)
Very exciting press release FLCR, very nice ! - eom
The limo 13 actors will call it quits soon
AWARD: The Arbitrator has decided and determined in full and final resolution of the
issues submitted for determination as follows: Respondent is liable and shall pay to
Claimant compensatory damages in the amount of $1,610.98; Respondent shall
reimburse Claimant in the amount of $175.00 for the filing fee previously paid to FINRA
Dispute Resolution; Respondent is liable and must deliver to Claimant a physical share
certificate for 152,380 of BCIT shares; and any and all relief not specifically addressed
herein
http://finraawardsonline.finra.org/viewdocument.aspx?DocNB=65553
Weebie, can you stickie post that post, informative relevant bcit info for all eyes to read.
VCEL - ibox updated
Congratulation Norm, You must have some good stuff brewing to get that much loot ! Looking forward to more News as you release it.
If An OTCBB Co Needs To Make A Run, I suggest Again Norm needs to Makes A Medical Marijuana Addition To Full Circle, CNBC Just ran Another Story that NIH Scientist Holds a Patent on the Items in MM.
It's a No Brainer.
link To Dr. MANNY on Fox News
http://video.foxnews.com/v/3880868148001/medical-marijuana-for-concussions/#sp=show-clips
Read the Conclusions on this Study Poster, Pretty Cool Stuff.
http://files.shareholder.com/downloads/ASTM/1479928754x0x501030/a2c45ba7-9c8e-46b0-af5e-7d73c6d47a33/HF-society-poster-final6.pdf
ASTM in the News
http://chronicle.augusta.com/latest-news/2014-06-19/stem-cell-trial-could-heal-hearts#.U6hTVtw4aU4.twitter
Stem cell trial could heal hearts
By Tom Corwin
Staff Writer
Thursday, June 19, 2014 8:35 PM
astm
GlobeNewswire
Aastrom Biosciences, Inc.
1 hour ago
ANN ARBOR, Mich., June 15, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, will hold an investor conference call and slide presentation on Monday, June 16, 2014 beginning at 8:30 AM EDT. The company will present an update and its strategic plans for the cell therapy and regenerative medicine business that it recently acquired from Sanofi.
What: Aastrom Biosciences, Inc., Investor Conference Call and Webcast
When: Monday, June 16, 2014, at 8:30 AM (EDT)
How: The conference call will be available live in the Investors section of the Aastrom website at http://investors.aastrom.com/events.cfm.
Please access the site at least 15 minutes prior to the scheduled start time in order to download the slide presentation and, if necessary, the required audio software.
To participate in the live call by telephone, please call (877) 312-5881 and reference Aastrom Biosciences Conference Call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate during the live call, a replay of the call will be available beginning June 16, 2014 at 11:30 AM (EDT) until June 20, 2014 at 11:59 PM (EDT) by calling (855) 859-2056, or from outside the U.S. by calling (404) 537-3406. The conference ID is 61387590. A copy of the presentation slides will be available in the Investors section of the Aastrom website at http://investors.aastrom.com/events.cfm.
astm news. wow, on a SUNDAY
Nevermind, just saw the citigroup chart on the hub, it too was June 9th, maybe stockcharts missed its electricity payments, lol
That is unusual, might need a new chart cut and paste, eom
lasers, any reason the chart in the ibox quit working? At least for me, it is not showing today's activity.
Did it just get a bear raid? 2nd time for a Monday morning slaughter, around 11am 80k went thru in one trading minute
ASTM looks like it wants to explode upward, nice, let's see what next week brings. :)
That is good news, Dino if you read this, Let's get it going :)
I hope mgmt announces mid next week, and a nice afternoon run today into the deep $5's would be narly.
ASTM short interest as of 5/15/2014 784,402, wonder after today's volume, what the actual short interest is.
52 week high is in the mid $17's
C'mon ceo Nick
Right news and $20's should be coming, maybe in six months or so,
IMO, ASTM is way oversold.
ASTM updated site, now 34 of 38 recruiting, only 4 more to go
http://clinicaltrials.gov/ct2/show/study/NCT01670981?term=aastrom&rank=9&show_locs=Y#locn
First time in two years it is at pre market, rather than after the bell. Must be a sign from the Heavens.
414k vol 4.48, one hour, one day, and a wake up, tic toc
179k vol 4.47 ASTM, looks like the 200dma is in todays reach, eom
lasers, it is wild that about 9 months ago, this stock ran up to .88 cents pre reverse split, and now its hanging at .21
Probably going to be very volatile, but the shorts have a high 600k position and lets see if they are made to cover.
I'd really be curious as to what Eastern Capital is thinking of, being they are one of ASTM biggest holders.
IMO, they got to be happier than a pig in chit right now.
lasers, Should ASTM be expecting any upgrades from the acquisition of this 44M revenue signing? What pps should be ASTM valued at from this?
Aastrom Biosciences : Researchers Submit Patent Application, "CD14+ Cell Compositions and Methods of Using Same", for Approval
http://www.4-traders.com/AASTROM-BIOSCIENCES-INC-14591271/news/Aastrom-Biosciences--Researchers-Submit-Patent-Application-CD14-Cell-Compositions-and-Methods-of-18315799/
Just found this posted from another thread, Last paragragh finds ASTM CEO saying no immediate equity raises.
http://www.xconomy.com/detroit/2014/04/25/in-need-of-revenues-aastrom-buys-sanofis-cell-therapy-products/
In Need Of Revenues, Aastrom Buys Sanofi’s Cell Therapy Products
Sarah Schmid4/25/14Follow @XconomyDET
More than a year after the failure of its lead program forced a major overhaul, Aastrom Biosciences (NASDAQ:ASTM) announced Monday it had acquired pharmaceutical giant Sanofi’s cell therapy and regenerative medicine business for $6.5 million.
“We’ve taken steps to strengthen Aastrom and broaden the business, and I think this transaction is a clear reflection of that,” says Nick Colangelo, Aastrom’s CEO.
As part of the deal, Aastrom of Ann Arbor, MI, obtained what was a legacy business left over from Sanofi’s $20 billion buyout of Genzyme. Aastrom receives the commercial rights to three products: Carticel, Epicele, and MACI. Carticel is an autologous chondrocyte implant marketed as a treatment for cartilage defects. Epicele is a permanent skin replacement product, and MACI is a cartilage repair product marketed in Europe. Colangelo says Aastrom also acquired manufacturing and development centers in Denmark and the United States.
“We’ve acquired some of the earliest FDA-approved autologous therapies,” Colangelo says, referring to products derived from a patient’s own tissues. “It’s a strong synergy. We’ve been working on autologous cell therapy for the life of the company.”
Colangelo says that the three products Aastrom purchased from Sanofi generated $44 million in revenue in 2013. That’s a drop in the ocean for Sanofi and its $140 billion market cap, but for Aastrom it’s a life preserver. The biotech plans to use the cash to pay for the ongoing development of therapies such as its Phase 2b study of ixmyelocel-T to treat a cardiovascular condition known as dilated cardiomyopathy.
Only $4 million of the purchase is payable in cash, with $2.5 million in the form of a promissory note, reflecting the small revenue stream the products are expected to deliver, as well as Aastrom’s own cash position. It had $8 million in the bank at the start of the year.
Aastrom will also inherit all of Sanofi’s employees who worked for its regenerative medicine and cell therapy division. As we reported on April 11, Aastrom recently appointed Ross Tubo as chief scientific officer. Tubo was formerly vice president of stem cell research and chemokine biology at Genzyme, where he oversaw R&D for two of the first FDA-approved autologous cellular therapies before the Sanofi takeover.
“It’s an interesting circle of life,” Colangelo says. “Ross left Harvard Medical School and helped develop these products with Genzyme. Now they end up right back in his lap.”
Colangelo says the acquisition has already sparked interest from investors, but Aastrom isn’t planning on raising another big round in the immediate future. “The commercial products will fund development, so it will reduce our need for capital in the long-term,” he adds. “I’m excited to do this kind of transformational transaction. It positions us to grow in ways we wouldn’t have been able to otherwise.”
Sarah Schmid is the editor of Xconomy Detroit. You can reach her at 313-570-9823 or sschmid@xconomy.com.
I agree Zilla, this was .88 back in August 2013, can easily get back there, $17's, nice informative posts from you. gl
MM will be a multi billion dollar industry here in the USA, already more than 20 states are on board, and 4 states have it their ballots for this summer.